Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

Gut Health & the Gut–Brain Axis

Category 14 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 12 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
12
Listings
14 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

Gut Health & the Gut–Brain Axis

Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis — van Lanen et al., Eur J Nutr 2021

Systematic review and meta-analysis — 12 controlled intervention studies (9 parallel, 3 crossover), 772 adults with IBS. Moderate evidence. Eur J Nutr 2021;60(6):3505–3522. DOI 10.1007/s00394-020-02473-0. Free full text in PubMed Central (PMC8354978) — open access, CC BY 4.0. Note: Trials were small, lasted 3 months at most and were hard to blind, with signs of publication bias; the review was funded by Unilever, where the authors worked.
What It Found
Pooled 12 controlled studies (772 adults with IBS) comparing a low-FODMAP diet with other diets. The low-FODMAP diet reduced overall IBS symptom severity (standardised mean difference −0.66, 95% CI −0.88 to −0.44), lowered the IBS Symptom Severity Score by about 45 points in the studies that used it, and improved IBS-specific quality of life (mean difference 4.93 points, 95% CI 1.77 to 8.08).
Why It Matters Here
Backs up the low-FODMAP diet taught by the FODMAP-trained dietitians in chapter 15 (Monash University and King's College London directories) and the national dietitian finders there; most relevant to adults with IBS thinking about a supervised low-FODMAP diet.
Systematic review and meta-analysis — 12 controlled intervention studies (9 parallel, 3 crossover), 772 adults with IBS. Moderate evidence. Eur J Nutr 2021;60(6):3505–3522. DOI 10.1007/s00394-020-02473-0. Free full text in PubMed Central (PMC8354978) — open access, CC BY 4.0. Note: Trials were small, lasted 3 months at most and were hard to blind, with signs of publication bias; the review was funded by Unilever, where the authors worked.

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility — Savarino et al., United European Gastroenterol J 2022

European clinical guideline — GRADE-assessed evidence review and Delphi consensus of 30 experts from 10 countries (31 statements). Moderate evidence. United European Gastroenterol J 2022;10(6):556–584. DOI 10.1002/ueg2.12259. Free full text in PubMed Central (PMC9278595) — open access, CC BY-NC-ND 4.0. Note: Covers diarrhoea-predominant IBS only; the diet, psychological-therapy, probiotic and FMT recommendations all rest on low-quality evidence.
What It Found
Europe's gastroenterology societies graded the evidence for diarrhoea-predominant IBS. They strongly recommend gut-directed psychological therapies (low-quality evidence, 89% agreement) and short-term use of a low-FODMAP diet when other measures fail (strong, low quality, 100%), conditionally support some probiotics (93%), and recommend against a gluten-free diet and against faecal microbiota transplant for IBS.
Why It Matters Here
Backs up the gastroenterologist finders, FODMAP-trained dietitians and GI psychologist directory in chapter 15, and supports the directory's message that FMT is for recurrent C. difficile, not IBS; most relevant to people with IBS-D and their clinicians.
European clinical guideline — GRADE-assessed evidence review and Delphi consensus of 30 experts from 10 countries (31 statements). Moderate evidence. United European Gastroenterol J 2022;10(6):556–584. DOI 10.1002/ueg2.12259. Free full text in PubMed Central (PMC9278595) — open access, CC BY-NC-ND 4.0. Note: Covers diarrhoea-predominant IBS only; the diet, psychological-therapy, probiotic and FMT recommendations all rest on low-quality evidence.

Assessing telephone-delivered cognitive–behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial — Everitt et al., Gut 2019

Multicentre randomised controlled trial — 558 adults with refractory IBS, three arms, 12-month follow-up. Moderate evidence. Gut 2019;68(9):1613–1623. DOI 10.1136/gutjnl-2018-317805. Free full text in PubMed Central (PMC6709776) — open access, CC BY-NC 4.0. Note: A single trial in which participants and therapists could not be blinded; 30% did not complete 12-month follow-up.
What It Found
558 UK adults whose IBS had not improved with first-line treatment were randomised to telephone CBT, web-based CBT with minimal therapist support, or usual care. At 12 months symptom scores (IBS-SSS) were 61.6 points lower with telephone CBT (95% CI 33.8 to 89.5) and 35.2 points lower with web CBT (95% CI 12.6 to 57.8) than with usual care; work and social functioning also improved, with no serious adverse reactions.
Why It Matters Here
Backs up the GI psychologists in chapter 15 (Rome Foundation GastroPsych directory) and CBT therapists found through chapter 05, and shows IBS-specific CBT can work by phone or online; most relevant to adults with long-standing IBS who cannot easily attend face-to-face therapy.
Multicentre randomised controlled trial — 558 adults with refractory IBS, three arms, 12-month follow-up. Moderate evidence. Gut 2019;68(9):1613–1623. DOI 10.1136/gutjnl-2018-317805. Free full text in PubMed Central (PMC6709776) — open access, CC BY-NC 4.0. Note: A single trial in which participants and therapists could not be blinded; 30% did not complete 12-month follow-up.

Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome — Lackner et al., Gastroenterology 2018

Randomised controlled trial (IBSOS) — 436 adults with refractory IBS at two US centres, three arms, 6-month follow-up. Moderate evidence. Gastroenterology 2018;155(1):47–57. DOI 10.1053/j.gastro.2018.03.063. Free full text in PubMed Central (PMC6035059). Note: All three groups, education included, improved similarly on the IBS symptom severity score; CBT's advantage was in global improvement ratings. Mostly white women at two US centres.
What It Found
436 adults with IBS were randomised to 10 sessions of standard CBT, 4 sessions of mostly home-based CBT, or 4 sessions of IBS education. Two weeks after treatment 61.0% of the home-based CBT group rated their gut symptoms moderately or substantially improved versus 43.5% with education; at 6 months gastroenterologists rated 58.4% versus 44.8% as improved. Home-based CBT was at least as effective as the longer clinic-based course.
Why It Matters Here
Backs up the GI psychologists in chapter 15 (Rome Foundation GastroPsych directory) and CBT therapists found through chapter 05; most relevant to people with IBS who want a shorter, mainly home-based course of CBT using a workbook.
Randomised controlled trial (IBSOS) — 436 adults with refractory IBS at two US centres, three arms, 6-month follow-up. Moderate evidence. Gastroenterology 2018;155(1):47–57. DOI 10.1053/j.gastro.2018.03.063. Free full text in PubMed Central (PMC6035059). Note: All three groups, education included, improved similarly on the IBS symptom severity score; CBT's advantage was in global improvement ratings. Mostly white women at two US centres.

The Efficacy of Hypnotherapy in the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis — Lee et al., J Neurogastroenterol Motil 2014

Systematic review and meta-analysis — 7 randomised trials, 374 people with IBS. Moderate evidence. J Neurogastroenterol Motil 2014;20(2):152–162. DOI 10.5056/jnm.2014.20.2.152. Free full text in PubMed Central (PMC4015203) — open access, CC BY-NC 3.0. Note: Few, small trials (all before 2014) that could not be blinded, with large differences between them; long-term benefit is uncertain.
What It Found
Pooled 7 randomised trials (374 people whose IBS had not responded to usual care) comparing hypnotherapy with conventional treatment or no treatment. At 3 months hypnotherapy reduced abdominal pain more than control (standardised mean difference −0.83, 95% CI −1.65 to −0.01), and 3 of 4 trials found greater improvement in overall gut symptoms; the effect at one year was not statistically clear.
Why It Matters Here
Backs up the psychogastroenterology clinicians in chapter 15 (Rome Foundation GastroPsych directory) and therapists found through the chapter 05 directories who offer gut-directed hypnotherapy; most relevant to people with persistent IBS interested in it.
Systematic review and meta-analysis — 7 randomised trials, 374 people with IBS. Moderate evidence. J Neurogastroenterol Motil 2014;20(2):152–162. DOI 10.5056/jnm.2014.20.2.152. Free full text in PubMed Central (PMC4015203) — open access, CC BY-NC 3.0. Note: Few, small trials (all before 2014) that could not be blinded, with large differences between them; long-term benefit is uncertain.

Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile) — Minkoff et al., Cochrane Database Syst Rev 2023

Cochrane systematic review and meta-analysis — 6 randomised trials, 320 adults. Strong evidence. Cochrane Database Syst Rev 2023;(4):CD013871. DOI 10.1002/14651858.CD013871.pub2. Free full text in PubMed Central (PMC10125800). Note: Only six trials; findings apply to adults with healthy immune systems, and the authors say registry data are needed on longer-term safety.
What It Found
Six randomised trials (320 adults) compared faecal microbiota transplant (FMT) with other treatments, mostly antibiotics, for recurrent C. difficile infection. FMT likely leads to a large increase in resolution of the infection (risk ratio 1.92, 95% CI 1.36 to 2.71; number needed to treat 3; moderate-certainty evidence). Serious adverse events and deaths were too few to judge safety with confidence.
Why It Matters Here
Backs up the regulated FMT services and guidance in chapter 15 (Birmingham Microbiome Treatment Centre, NICE, TGA), the AGA FMT registry in chapter 01 and the C. diff advocacy and FMT research charities in chapter 16; most relevant to people with recurring C. difficile.
Cochrane systematic review and meta-analysis — 6 randomised trials, 320 adults. Strong evidence. Cochrane Database Syst Rev 2023;(4):CD013871. DOI 10.1002/14651858.CD013871.pub2. Free full text in PubMed Central (PMC10125800). Note: Only six trials; findings apply to adults with healthy immune systems, and the authors say registry data are needed on longer-term safety.

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice — Cammarota et al., Gut 2019

International consensus statement — 29 experts from Europe, North America and Australia; Delphi process, 40 statements (17 GRADE-assessed). Moderate evidence. Gut 2019;68(12):2111–2121. DOI 10.1136/gutjnl-2019-319548. Free full text in PubMed Central (PMC6872442) — open access, CC BY-NC 4.0. Note: About safety and organisation rather than effectiveness; 23 of the 40 statements rest on expert opinion, and regulation differs by country.
What It Found
Experts agreed how stool banks should run so that FMT is safe, traceable and widely available: healthy donors not chosen by the patient, who pass a health questionnaire plus blood and stool tests (repeated every 8–12 weeks), approval by national regulators, supply through doctors rather than direct to patients, donor and recipient records kept for at least 10 years, and registries to track side effects.
Why It Matters Here
Backs up the regulated FMT programmes and regulator pages in chapter 15 (Birmingham Microbiome Treatment Centre, TGA) and gives a checklist for judging clinics found through the FMT directory in chapter 01; relevant to patients and clinicians.
International consensus statement — 29 experts from Europe, North America and Australia; Delphi process, 40 statements (17 GRADE-assessed). Moderate evidence. Gut 2019;68(12):2111–2121. DOI 10.1136/gutjnl-2019-319548. Free full text in PubMed Central (PMC6872442) — open access, CC BY-NC 4.0. Note: About safety and organisation rather than effectiveness; 23 of the 40 statements rest on expert opinion, and regulation differs by country.

Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry — Kelly et al., Gastroenterology 2021

Prospective observational registry — 259 people treated with FMT for C. difficile at 20 North American sites. Early evidence. Gastroenterology 2021;160(1):183–192.e3. DOI 10.1053/j.gastro.2020.09.038. Free full text in PubMed Central (PMC8034505). Note: Observational with no comparison group; many people were lost to follow-up and the sites were larger centres with an interest in FMT.
What It Found
First results from the AGA-led FMT National Registry: of 259 people given FMT for C. difficile at 20 sites, 90% of those followed for one month had resolution, 98% of them after a single FMT, and 4% of those initially resolved who were followed to six months had a recurrence. Hospital admission possibly related to FMT occurred in 1%, and new IBS or IBD was diagnosed in 1% each by six months.
Why It Matters Here
Backs up the AGA FMT National Registry listed in chapter 01 and the regulated FMT services in chapter 15; most relevant to people weighing FMT for recurrent C. difficile who want real-world results alongside trial data.
Prospective observational registry — 259 people treated with FMT for C. difficile at 20 North American sites. Early evidence. Gastroenterology 2021;160(1):183–192.e3. DOI 10.1053/j.gastro.2020.09.038. Free full text in PubMed Central (PMC8034505). Note: Observational with no comparison group; many people were lost to follow-up and the sites were larger centres with an interest in FMT.

Probiotics for the prevention of pediatric antibiotic-associated diarrhea — Guo et al., Cochrane Database Syst Rev 2019

Cochrane systematic review and meta-analysis — 33 randomised trials, 6,352 children. Strong evidence. Cochrane Database Syst Rev 2019;(4):CD004827. DOI 10.1002/14651858.CD004827.pub5. Free full text in PubMed Central (PMC6490796). Note: 20 of 33 trials had high risk of bias; serious harms have been reported outside trials in very ill or immunocompromised children.
What It Found
Across 33 trials (6,352 children taking antibiotics), probiotics reduced antibiotic-associated diarrhoea from 19% to 8% (risk ratio 0.45, 95% CI 0.36 to 0.56; number needed to treat 9; moderate-certainty evidence). Benefit looked larger with higher-dose products such as Lactobacillus rhamnosus or Saccharomyces boulardii, which the authors say needs confirming; no serious adverse events were attributed to probiotics.
Why It Matters Here
Backs up the evidence-graded probiotic guides in chapter 15 (ISAPP, Clinical Guide to Probiotic Products, NIH fact sheet, WGO guideline), which stress that benefit depends on the specific product and situation; most relevant to parents and clinicians.
Cochrane systematic review and meta-analysis — 33 randomised trials, 6,352 children. Strong evidence. Cochrane Database Syst Rev 2019;(4):CD004827. DOI 10.1002/14651858.CD004827.pub5. Free full text in PubMed Central (PMC6490796). Note: 20 of 33 trials had high risk of bias; serious harms have been reported outside trials in very ill or immunocompromised children.

The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease — Penny et al., Gut 2026

National clinical guideline — multidisciplinary panel from the UK, Sweden, Italy and Australia; 15 GRADE-assessed recommendations, 19 good-practice statements and 6 expert opinions, each voted on by a consensus group. Moderate evidence. Gut 2026 (published online 9 July 2026). Free full text at the publisher — open access, CC BY-NC 4.0. Note: Several key recommendations, including the life-long gluten-free diet, rest on low-certainty evidence; it covers adults only, and the no-biopsy route is optional.
What It Found
The British Society of Gastroenterology's updated guideline for adults with coeliac disease recommends a life-long gluten-free diet to improve symptoms and quality of life and reduce complications (strong recommendation, low-certainty evidence), signposting people at diagnosis to an established advocacy group such as Coeliac UK, and regular follow-up for up to 2 years. Adults with very high tTG antibody levels may be diagnosed without a biopsy after shared decision-making.
Why It Matters Here
Backs up the coeliac charities and local groups in chapter 15 (Coeliac UK, Coeliac Australia, AOECS societies), which it advises pointing people to at diagnosis, and the coeliac practitioner finder; most relevant to adults newly diagnosed with coeliac disease.
National clinical guideline — multidisciplinary panel from the UK, Sweden, Italy and Australia; 15 GRADE-assessed recommendations, 19 good-practice statements and 6 expert opinions, each voted on by a consensus group. Moderate evidence. Gut 2026 (published online 9 July 2026). Free full text at the publisher — open access, CC BY-NC 4.0. Note: Several key recommendations, including the life-long gluten-free diet, rest on low-certainty evidence; it covers adults only, and the no-biopsy route is optional.

Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK — Kapasi et al., Frontline Gastroenterol 2020

National consensus standards — modified Delphi (3 rounds, 28 voters) informed by a survey of 151 professionals and 689 patients; 59 statements. Moderate evidence. Frontline Gastroenterol 2020;11(3):178–187 (online 2019). DOI 10.1136/flgastro-2019-101260. Free full text in PubMed Central (PMC7223296) — open access, CC BY-NC 4.0. Note: Expert and patient consensus, not trial evidence; led and funded by Crohn's & Colitis UK, which is listed in the directory.
What It Found
IBD UK, an alliance of patient and professional organisations, agreed 59 standards of care through a Delphi process informed by 689 patients and 151 professionals. They include that newly diagnosed people be signposted to patient organisations and be able to see a psychologist and specialist dietitian when needed, and that patients get clear information for self-managing flares and a telephone/email advice line.
Why It Matters Here
Backs up the IBD charities' information hubs, local networks and support groups in chapter 15 and the IBD support groups in chapter 06; most relevant to people with Crohn's or colitis, and families, checking what good care should include.
National consensus standards — modified Delphi (3 rounds, 28 voters) informed by a survey of 151 professionals and 689 patients; 59 statements. Moderate evidence. Frontline Gastroenterol 2020;11(3):178–187 (online 2019). DOI 10.1136/flgastro-2019-101260. Free full text in PubMed Central (PMC7223296) — open access, CC BY-NC 4.0. Note: Expert and patient consensus, not trial evidence; led and funded by Crohn's & Colitis UK, which is listed in the directory.

The Microbiota-Gut-Brain Axis: From Motility to Mood — Margolis et al., Gastroenterology 2021

Narrative review of mechanistic, animal and human studies. Early evidence. Gastroenterology 2021;160(5):1486–1501. DOI 10.1053/j.gastro.2020.10.066. Free full text in PubMed Central (PMC8634751). Note: Narrative review of mostly animal and early human research; it explains possible mechanisms but does not show that any gut–brain treatment works.
What It Found
Three gut–brain researchers explain how the gut, its microbes and the brain signal to each other (vagus nerve, immune system, microbial metabolites, serotonin) and how this may relate to IBS and depression. They stress that the best-studied pathways come largely from animal models, that a causal role for the microbiome 'remains to be determined', and that clinically significant effects of probiotics for psychiatric disorders have not been shown.
Why It Matters Here
Backs up the gut–brain science listings in chapter 15 (Rome Foundation, APC Microbiome Ireland, Gut Microbiota for Health) and gives context for food-and-mood resources in chapter 10; useful for anyone wanting an honest picture of what is and is not yet known.
Narrative review of mechanistic, animal and human studies. Early evidence. Gastroenterology 2021;160(5):1486–1501. DOI 10.1053/j.gastro.2020.10.066. Free full text in PubMed Central (PMC8634751). Note: Narrative review of mostly animal and early human research; it explains possible mechanisms but does not show that any gut–brain treatment works.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource